| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |
|
|
|
|
|||||||||||||
|
|
|||||||||||||||
CARDIOVASCULAR MEDICINE |
1 Royal Shrewsbury Hospital, Shrewsbury, UK
2 Our Lady’s Hospital for Sick Children, Dublin, Republic of Ireland
3 The Cardiothoracic Centre, Liverpool, UK
Correspondence to:
Correspondence to:
Dr Peter T Wilmshurst
Royal Shrewsbury Hospital, Shrewsbury SY3 8XQ, UK; peter.wilmshurst{at}rsh.nhs.uk
Objective: To report the clinical events leading to alteration of an anticoagulation regimen for patients undergoing transcatheter closure of an atrial shunt and how this affected migraine symptoms after the closure procedure.
Method: Audit of a change of anticoagulant regimen.
Results: In the first few weeks after a closure procedure migraine frequency and severity increased despite treatment with aspirin for six months in 71 patients. Severe attacks of migraine with aura, including status migrainosus, in the first few weeks after transcatheter closure were terminated by addition of clopidogrel to aspirin treatment. Therefore, the anticoagulant regimen was changed with addition of clopidogrel for the first month after the closure procedure (90 procedures in 89 patients). Fewer patients had migraine with aura in the first month after transcatheter closure when taking the combination of clopidogrel and aspirin compared with aspirin alone (11 of 90 (12.2%) v 30 of 71 (42.3%), p < 0.001). Episodes of migraine with aura were more severe and more frequent in patients taking aspirin alone.
Conclusion: The combination of clopidogrel for four weeks and aspirin for six months is superior to aspirin alone for six months for preventing migraine with aura after transcatheter closure of an atrial shunt. This beneficial effect of a powerful inhibitor of platelet aggregation suggests that platelets may have a role in pathogenesis of migraine. This may be because of an effect on serotonin stores. Whether clopidogrel has a role in treatment of migraine in other clinical situations requires investigation.
Keywords: atrial septal defect; clopidogrel; migraine; persistent foramen ovale; transcatheter closure
This article has been cited by other articles:
|
|
 |
|
  T. Rundek, M. S.V. Elkind, M. R. Di Tullio, E. Carrera, Z. Jin, R. L. Sacco, and S. Homma Patent Foramen Ovale and Migraine: A Cross-Sectional Study From the Northern Manhattan Study (NOMAS) Circulation, September 30, 2008; 118(14): 1419 - 1424. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Dowson, M. J. Mullen, R. Peatfield, K. Muir, A. A. Khan, C. Wells, S. L. Lipscombe, T. Rees, J. V. De Giovanni, W. L. Morrison, et al. Migraine Intervention With STARFlex Technology (MIST) Trial: A Prospective, Multicenter, Double-Blind, Sham-Controlled Trial to Evaluate the Effectiveness of Patent Foramen Ovale Closure With STARFlex Septal Repair Implant to Resolve Refractory Migraine Headache Circulation, March 18, 2008; 117(11): 1397 - 1404. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. D. Carroll Migraine Intervention With STARFlex Technology Trial: A Controversial Trial of Migraine and Patent Foramen Ovale Closure Circulation, March 18, 2008; 117(11): 1358 - 1360. [Full Text] [PDF]
|
|
|
|
 |
|
 B. Lapergue, C. Rosso, L. Hadrane, J. Labreuche, H. Abboud, E. Brochet, J. -M. Juliard, and P. Amarenco Frequency of migraine attacks following stroke starts to decrease before PFO closure. Neurology, September 26, 2006; 67(6): 1099 - 1100. [Full Text] [PDF]
|
|
Read all eLetters
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |
